

CO-CHAIR & MODERATOR  
Saakshi Khattri, MBBS, MD, FAAD, FACR

CO-CHAIRS & PRESENTERS  
Marla Dubinsky, MD  
Emma Guttman-Yassky, MD, PhD  
Alexis Ogdie, MD, MSCE

PeerView  
Live

CME/AAPA

# Interdisciplinary Approaches to the Management of Immune-Mediated Inflammatory Diseases

*Addressing Shared Pathophysiology With JAK Inhibitors*

Wednesday, May 22, 2024

7:00 PM - 8:00 PM CDT

Virtual Conference; PRE-REGISTER TODAY! [Click Here](#)

Aline Charabaty, MD, AGAF, FACG

Associate Professor of Clinical Medicine  
Division of Gastroenterology and Hepatology  
Johns Hopkins School of Medicine  
Clinical Director of the IBD Center  
Johns Hopkins - Sibley Memorial Hospital  
Washington DC

## Activity Description

Immune-mediated inflammatory diseases share immunologic, pathophysiologic, and clinical features and often co-occur. IMIDs include inflammatory bowel disease (IBD), psoriatic arthritis (PsA), rheumatoid arthritis (RA), the spondyloarthritis (SpA) disease spectrum, atopic dermatitis (AD), and others. The introduction of biologic agents targeting different inflammatory pathways revolutionized the management of IMIDs. However, there are several limitations to these agents, including administration, high costs, and high rates of loss of response and disease relapse. Small-molecule, targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), including JAK inhibitors, have the capacity to overcome some of the limitations of biologic agents.


In this activity, an expert faculty member will explore the mechanism by which these agents address the underlying pathophysiology shared by IMIDs, their safety and efficacy, and how these agents may be incorporated into individualized treatment plans for patients, particularly for patients with more than one IMID. In addition, the expert will provide strategies to improve interdisciplinary collaboration and engage patients in shared decision-making to achieve optimal care and outcomes.

## Educational Objectives

Upon completion of this activity, participants should be better able to:

- Discuss the rationale and clinical evidence for selectively targeting Janus kinases (JAKs) in the treatment of various immune-mediated inflammatory diseases (IMID), considering their shared pathophysiology and immunologic underpinnings
- Describe the role of JAK inhibitors in the treatment of various IMIDs, considering their safety and efficacy data
- Create appropriate treatment plans for individual patients with various IMIDs, recognizing those who might benefit from the use of therapy with JAK inhibitors
- Implement strategies that involve a team approach to involve patients in the shared decision-making process for their IMID management

## Accreditation, Support, and Credit

 In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Crohn's and Colitis Foundation, National Eczema Association, and Spondylitis Association of America. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


## Support

This activity is supported by an independent educational grant from AbbVie.

## Physicians

PVI, PeerView Institute for Medical Education, designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Physician Assistants

 PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.